| Name | CP-547632 |
| Description | CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity. |
| In vitro | CP-547632 (1-1000 nM ; 1 h) suppresses VEGF-induced VEGFR-2 phosphorylation in a concentration-dependent manner (IC50: 6 nM). [1] |
| In vivo | CP-547632 (oral ; 50 mg/kg) yieldes plasma concentrations above 500 ng/ml for 12 hours. CP-547632 (p.o. ; 6.25-100 mg/kg/day ; for 10-24 days) causes a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90.0 mg/mL (169.0 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.51 mM), Sonication is recommended.
|
| Keywords | VEGFR-2 | VEGFR2 | PDGFRβ | FGFR | CP-547632 | CP547632 | CP 547632 | BTK | bFGFR |
| Inhibitors Related | Ribociclib | Amlexanox | Nintedanib | Regorafenib monohydrate | Sorafenib | Ferulic Acid | Regorafenib | Sorafenib tosylate | Formononetin | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |